Volume 101, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



rVSVΔG-ZEBOV-GP vaccine is a live recombinant (r) vesicular stomatitis virus (VSV), where the VSV G protein is replaced with the Zaire Ebola virus (ZEBOV) glycoprotein (GP). For vaccine immunogenicity testing, clinical trial sera collected during an active ZEBOV outbreak underwent gamma irradiation (GI) before testing in biosafety level 2 laboratories to inactivate possible wild-type ZEBOV. Before irradiating pivotal trial samples, two independent studies evaluated the impact of GI (50 kGy) on binding ZEBOV-GP (ELISA) antibodies against rVSVΔG-ZEBOV-GP, using sera from a North American phase 1 study. Gamma irradiation was associated with slightly higher antibody concentrations in pre-vaccination samples and slightly lower concentrations postvaccination. Results indicate that GI is a viable method for treating samples from regions where filoviruses are endemic, with minor effects on antibody titers. The impact of GI on immunogenicity analyses should be considered when interpreting data from irradiated specimens.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Morens DM, Fauci AS, , 2013. Emerging infectious diseases: threats to human health and global stability. PLoS Pathog 9: e1003467. [Google Scholar]
  2. Cutts T, Grolla A, Jones S, Cook BW, Qiu X, Theriault SS, , 2016. Inactivation of Zaire ebolavirus variant Makona in human serum samples analyzed by enzyme-linked immunosorbent assay. J Infect Dis 214 (Suppl 3): S218S221. [Google Scholar]
  3. Centers for Disease Control and Prevention, Division of Select Agents and Toxins, Animal and Plant Health Inspection Service, Agricultural Select Agent Program, 2017. Guidance on the Inactivation or Removal of Select Agents and Toxins for Future Use. Available at: https://www.selectagents.gov/resources/Inactivation_Guidance.pdf. Accessed July 10, 2018. [Google Scholar]
  4. Agnandji ST, 2016. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 374: 16471660. [Google Scholar]
  5. ElSherif MS, 2017. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ 189: E819E827. [Google Scholar]
  6. Regules J, 2017. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med 376: 330341. [Google Scholar]
  7. Heppner DG, Jr. 2017. Safety and immunogenicity of the rVSVΔG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis 17: 854866. [Google Scholar]
  8. Huttner A, 2015. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 15: 11561166. [Google Scholar]
  9. Henao-Restrepo AM, 2017. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola ca suffit!). Lancet 389: 505518. [Google Scholar]
  10. Kennedy SB, 2017. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med 377: 14381447. [Google Scholar]
  11. Samai M, 2018. The Sierra Leone trial to introduce a vaccine against Ebola: an evaluation of rVSVΔG-ZEBOV-GP vaccine tolerability and safety during the West Africa Ebola outbreak. J Infect Dis 217 (Suppl 1): S6S15. [Google Scholar]
  12. Halperin SA, 2017. Six-month safety data of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J Infect Dis 215: 17891798. [Google Scholar]
  13. Elliott LH, McCormick JB, Johnson KM, , 1982. Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. J Clin Microbiol 16: 704708. [Google Scholar]
  14. Lupton HW, , 1981. Inactivation of Ebola virus with 60Co irradiation. J Infect Dis 143: 291. [Google Scholar]
  15. Mahanty S, Kalwar R, Rollin PE, , 1999. Cytokine measurement in biological samples after physicochemical treatment for inactivation of biosafety level 4 viral agents. J Med Virol 59: 341345. [Google Scholar]
  16. Smeltzer CC, Lukinova NI, Towcimak ND, Yan X, Mann DM, Drohan WN, Griko YV, , 2015. Effect of gamma irradiation on the structural stability and functional activity of plasma-derived IgG. Biologicals 43: 242249. [Google Scholar]
  17. David SC, Lau J, Singleton EV, Babb R, Davies J, Hirst TR, McColl SR, Paton JC, Alsharifi M, , 2017. The effect of gamma-irradiation conditions on the immunogenicity of whole-inactivated influenza A virus vaccine. Vaccine 35: 10711079. [Google Scholar]
  18. Hume AJ, Ames J, Rennick LJ, Duprex WP, Marzi A, Tonkiss J, Muhlberger E, , 2016. Inactivation of RNA viruses by gamma irradiation: a study on mitigating factors. Viruses 8: E204. [Google Scholar]

Data & Media loading...

Supplemental tables and figure

  • Received : 25 Jan 2019
  • Accepted : 01 Apr 2019
  • Published online : 03 Jun 2019

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error